A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Launched by BRISTOL-MYERS SQUIBB · Feb 8, 2022

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and high-risk features must have failed at least 2 lines of prior therapy and participants with CLL or SLL and standard risk features must have failed at least 3 lines of prior therapy
• • Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
• • Either currently has central vascular access or is a candidate to receive central vascular access or peripheral vascular access for leukapheresis procedure
• • Has recovery to Grade ≤ 1 or baseline of any non-hematologic toxicities due to previous therapy, except alopecia (any Grade acceptable) and peripheral neuropathy (Grade ≤ 2 acceptable)
• Exclusion Criteria:
• • Any condition, including active or uncontrolled infection, or the presence of laboratory abnormalities, that places the subject at unacceptable risk if they were to participate in the study
• • Systemic fungal, bacterial, viral, or other infection that is not controlled
• • Active autoimmune disease requiring immunosuppressive therapy
• • Progressive deep vein thrombosis or pulmonary embolism requiring treatment, but not yet on a stable anticoagulation regimen
• • Other protocol-defined inclusion/exclusion criteria apply